



Drug Utilization Review Board Meeting Minutes May 7, 2024

DUR Board Members in attendance:

In person: Marin Broucek, M.D., Charles Moore, R.P., Jennifer Meyfeldt, M.D., Virtual: Dave Randolph, R.P.

DUR Board Members not in attendance: Tom Dunn, R.P., Robert Wergin, M.D.

State attendees: Carisa Schweitzer Masek, R.P., Deputy Director Population Health; Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees in person: Jamie Benson, R.P., Nebraska Total Care; Nikia Bennette-Carter, R.P., Magellan Rx Management; Shaleigh Hammons, Account Manager, Magellan RX Management; Shannon Nelson, R.P., Molina Healthcare; Bernadette Ueda, R.P., United Health Care.

Public visitors in attendance in person: Janie Huff, Madrigal; Camille Kerr, Regeneron. Other virtual attendees.

I. Opening and Introductions

The meeting was called to order at 6:30 pm. A copy of the Open-Meetings Act was available. Dr. Marin Broucek was introduced as a new DUR Board member. Introductions were made by the Board and attendees. Jennifer Meyfeldt announced that this is her last DUR as she will be relocating.

II. Conflict of Interest

No changes in conflict of interest were declared.

III. Agenda approval

The minutes were unanimously approved.

IV. Approval of Minutes from DUR Board February 13, 2024 meeting.

Voting as follows: Broucek, abstain; Meyfeldt, yes; Moore, yes; Randolph, yes.

V. Special Topics

Carisa Schweitzer Masek gave an update on legislative bill 204 which requires an increased pharmacy dispensing fee as of July 1 with an amendment of limiting to independent pharmacies. A cost of dispensing survey pharmacy survey must also be administered every two years to create standard dispensing fees.

VI. Retrospective DUR:

Data on prescribed lithium and lithium level monitoring was presented. Data was also compared among prescribers and their specialty type. An updated data review on opioid and benzodiazepine concomitant prescribing was also presented.

VII. Prospective DUR:

The State presented a prior authorization form for Wegovy for the new indication of reduction of risk of cardiovascular adverse events. The State also presented the annual review of the Immunomodulator prior authorization form. Particularly noted is the new indication for Xolair in the treatment of food-related allergies.

VIII. Future Meeting Date

The next meeting is scheduled for July 9th, 2024.

IX. Concerns & Comments

Board: Charlie Moore states that he is still seeing the reimbursement for Medicaid pharmacy claims is still seeing lower than what the pharmacy paid for the medication.

DUR Director and State representatives: It was announced that Board members Tom Dunn and Tim Bourke have resigned and thank them for their work.

Magellan representatives: None

Managed Care Organization (MCO) representatives: None

Public attendees: None

X. Adjournment

The meeting was adjourned by Schweitzer-Masek at 7:36 pm.